TABLE 1.
Baseline characteristics of CHB patients
|
Total (N = 73) |
Part A (N = 48) |
Part B (N = 25) |
|
|---|---|---|---|
| Sex, n (%) | |||
| Female | 34 (46.6) | 24 (50) | 10 (40) |
| Male | 39 (53.4) | 24 (50) | 15 (60) |
| Age, years (SD) | 39.7 (9.8) | 39.8 (9.9) | 39.3 (9.8) |
| Race, n (%) | |||
| Asian | 22 (28.2) | 15 (31.3) | 7 (28.0) |
| Black | 11 (15.1) | 8 (16.7) | 3 (12.0) |
| White | 40 (54.8) | 25 (52.1) | 15 (60.0) |
| HBeAg status, n (%) | |||
| Negative | 64 (91.8) | 45 (93.8) | 19 (76) |
| Positive | 9 (8.2) | 3 (6.2) | 6 (24) |
| Anti‐HBeAg status, n (%) | |||
| Negative | 8 (11.0) | 3 (6.3) | 5 (20.0) |
| Positive | 62 (84.9) | 43 (89.6) | 19 (76.0) |
| Unknown | 3 (4.1) | 2 (4.2) | 1 (4.0) |
| HBV genotype, n (%) | |||
| A | 23 (31.5) | 15 (31.3) | 8 (32.0) |
| B | 8 (11.0) | 5 (10.4) | 3 (12.0) |
| C | 10 (13.7) | 7 (14.6) | 3 (12.0) |
| D | 7 (9.6) | 5 (10.4) | 2 (8.0) |
| E | 4 (5.5) | 3 (6.3) | 1 (4.0) |
| Unknown | 21 (28.8) | 13 (27.1) | 8 (32.0) |
| Alanine transaminase, U/L (SD) | 29 (16) | 28 (12) | 31 (23) |
| HBV DNA, log10 IU/ml (SD) | |||
| HBeAg‐positive | 7.42 (1.56) | 7.55 (0.78) | 7.36 (1.91) |
| HBeAg‐negative | 3.71 (0.77) | 3.80 (0.79) | 3.50 (0.68) |
| HBsAg, IU/ml (SD) | |||
| HBeAg‐positive | 4.02 (1.12) | 4.09 (0.40) | 3.98 (1.39) |
| HBeAg‐negative | 3.47 (0.67) | 3.41 (0.68) | 3.61 (0.63) |
| HBV RNA, copies/ml (SD) | |||
| HBeAg‐positive | 6.06 (1.19) | 6.15 (0.75) | 6.02 (1.42) |
| HBeAg‐negative | 0.85 (1.79) | 1.10 (1.74) | 0.24 (1.80) |
| HBcrAg, log10 U/ml (SD) | |||
| HBeAg‐positive | 7.48 (0.65) | 7.77 (0.23) | 7.34 (0.77) |
| HBeAg‐negative | 2.17 (1.66) | 2.36 (1.68) | 1.72 (1.56) |
Abbreviations: HBcrAg, hepatitis B core‐related antigen; HBeAg, hepatitis B envelope antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; SD, standard deviation.